Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 2Unknown 1Completed 1

Sponsor Class

OTHER 34INDUSTRY 6OTHER_GOV 2NETWORK 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Cisplatin 15Paclitaxel 14Taxes 10Cyclophosphamide 9Carboplatin 9Gemcitabine 7Platinum 61,2-diaminocyclohexaneplatinum II citrate 6Trastuzumab 5Radiotherapy 5Oxaliplatin 5Doxorubicin 5Docetaxel 5Cytarabine 5Capecitabine 5Brachytherapy 5fludarabine 4Rituximab 4Radiosurgery 4Fluorouracil 4Dexamethasone 4Watchful Waiting 3Radiotherapy, Intensity-Modulated 3Pemetrexed 3Nimorazole 3Lenalidomide 3Imatinib Mesylate 3Idarubicin 3Gene Expression Profiling 3thymoglobulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × NETWORK × Azacitidine × Clear all
NCT01556477 2012-03-16

The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).

Nordic MDS Group

Phase 2 Unknown
72 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡